Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a multicentric International Phase III,Long term open label study(12 months)assessing
the long-term safety and efficacy of BF2.649 (Pitolisant)in the treatment of Excessive
Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.